Complement Therapeutics

Complement Therapeutics is a preclinical stage biotechnology company headquartered in Germany with subsidiaries in the UK and the USA. The company specializes in the development of novel therapeutics for complement-mediated diseases. Complement Therapeutics is a spin-out from the University of Manchester and was founded by leading experts in the complement system. The company's lead investigational product, CTx001, is an AAV gene therapy for geographic atrophy, a form of dry age-related macular degeneration.

Complement Therapeutics leverages a unique quantification methodology called the Complement Precision Medicine (CPM) platform to enable the quantification of over 30 complement cascade proteins. This allows for more precise diagnosis and monitoring of disease. The company is also exploring potential therapeutic opportunities in other complement-mediated conditions, including chronic renal disease and neurological diseases such as multiple sclerosis and Alzheimer's disease.

Complement Therapeutics is a biotechnology company dedicated to developing novel therapies for complement-mediated diseases, including geographic atrophy, a leading cause of blindness. They leverage their pioneering research into novel targets within the complement cascade to create innovative treatments that address unmet needs in a wide range of conditions.

Complement Therapeutics fosters a collaborative and innovative culture, built on the pioneering research of its founders. The company values a team-oriented approach and seeks to attract highly skilled individuals with a passion for developing life-changing treatments for complement-mediated diseases. The company's commitment to scientific excellence, coupled with a focus on patient-centricity, creates a dynamic and purpose-driven work environment.